



Australian Government
Department of Veterans' Affairs

Compensation & Income Support Policy Branch

SOP Bulletin No. 206

14 January 2019

THE FOLLOWING RMA SOPS TAKE EFFECT ON 28 JANUARY, 2019

New SOPs	Nil
Revocations & Replacements	Chondromalacia patella Iliotibial band syndrome Human immunodeficiency virus infection Internal derangement of the knee Dupuytren disease Hypopituitarism
Amendments	Sarcoidosis Localised sclerosis*

* Date of effect 23 July 2018

NOTEWORTHY FEATURES

Chondromalacia patella

Revocation – 1 & 2 of 2019

Replaces 79 & 80 of 2010

- There is a new RH only factor (onset and worsening) for being obese.
- For the trauma/injury/dislocation factors the time frame between event and onset has been made the same in the RH and BOP SOPs.
- In the running factors the distance per week has been made the same as in other overuse SOPs, at 30 (RH) and 60 (BOP) km per week.

Iliotibial band syndrome

Revocation – 3 & 4 of 2019

Replaces 34 & 35 of 2010

- New onset and worsening factors have been added for:
 - cycling (for a baseline amount and for a sudden increase) – RH and BOP;
 - knee reconstruction surgery as specified – RH and BOP;
 - weakness or paralysis of an abductor muscle of the hip – RH only; and
 - varus malalignment or thrust of the knee – RH only.
- The running factor has the same changes as for chondromalacia patella (30 & 60 km/wk).

Human immunodeficiency virus infection

Revocation – 5 & 6 of 2019

Replaces 5 & 6 of 2010

- The SOP name has been changed, by adding the word 'infection'.
- There are two new onset factors for:
 - Prior anogenital disease (as specified); and
 - Use of depot medroxyprogesterone acetate contraception.
- In the RH SOP the previously separate worsening factors for malaria and tuberculosis have been combined into a specified infections factors, with three new infections added to the list. There are no equivalent changes in the BOP SOP, which retains a tuberculosis worsening factor (and has no malaria factor).

Internal derangement of the knee**Revocation – 7 & 8 of 2019**

Replaces 51 & 52 of 2010

- There are no material changes, except for an extension of the time allowed from acute injury to onset or worsening, from 6 months to one year.

Dupuytren disease**Revocation – 9 & 10 of 2019**

Replaces 57 & 58 of 2010

- The SOP name has been changed, from Dupuytren's disease.
- The smoking and alcohol consumption factors have been updated to the now standard format, with a change to the alcohol dose.
- A new factor has been added for alcohol use disorder.
- Alcoholic liver disease has been retained as a factor in the BOP SOP, but in the RH SOP this factor has been extended to cover cirrhosis or steatohepatitis from any cause.
- The factors for manual activity/vibration and for diabetes, previously RH only, have been added to the BOP SOP.
- Other new factors have been added for:
 - Epilepsy – RH and BOP;
 - Treatment with Vemurafenib (mostly used to treat melanoma) – RH and BOP;
 - Psoriasis – RH only; and
 - Treatment with phenobarbital (as specified) – RH only.

Hypopituitarism**Revocation – 11 & 12 of 2019**

Replaces 76 & 77 of 2009

- The definition has been reformatted and now also contains additional information on the hormones involved and the clinical presentation.
- There have been minor modifications to a range of existing factors.
- No new factors have been added. A BOP factor for cocaine use has been removed.

Sarcoidosis**Amendment – 13 & 14 of 2019**

Amends 59 & 60 of 2016

- The changes follow a focussed investigation into cancer/cancer treatment and sarcoidosis.
- In both the RH and BOP SOPs the existing factors for interferon have been changed to a specified drugs factor, with a list of specific anti-cancer agents.
- In the RH SOP new onset and worsening factors have been added for:
 - Immunotherapy or targeted therapy for cancer (as defined); and
 - Having a malignant neoplasm.

Localised sclerosis**Amendment – 15 & 16 of 2019**

Amends 61 & 62 of 2018

- The amendments are to correct typographical errors only (replacing 'systemic sclerosis' with 'localised sclerosis' in the factors concerning specified drugs). The date of effect has been set to the date the previous revocation SOPs took effect, 23 July 2018.

Contact for this bulletin:

Dr Jon Kelley

X470412